Filter Results
:
(298)
Show Results For
-
All HBS Web
(298)
- People (1)
- News (81)
- Research (185)
- Multimedia (3)
- Faculty Publications (123)
Show Results For
-
All HBS Web
(298)
- People (1)
- News (81)
- Research (185)
- Multimedia (3)
- Faculty Publications (123)
- 01 Dec 2010
- News
You Are What You Eat
Writing in the magazine Pig Progress (September 23, 2010), Austria-based John Hodges (AMP 52, 1967),an expert on genetics and ethics in agriculture, food, and the environment, warned that the current system of agribusiness is untenable....
View Details
- 01 Sep 2008
- News
Mara Aspinall
1,500-person division is a leader in the emerging field of personalized medicine, which treats cancer and other diseases with customized therapies that take into account the patient’s specific genetic traits. With HBS professor Richard...
View Details
- Web
Timeline - Race, Gender & Equity
1985 USDA approves the sale of the first genetically altered organism 1986 Immigration Reform and Control Act prohibits employers with more than three employees from discriminating against anyone (except unauthorized immigrants) on the...
View Details
- 10 Dec 2010
- News
Notes from the Trenches
Executive Director Mike Roberts, the lineup lost no time in getting down to brass tacks with the SRO student crowd of would-be entrepreneurs. Paris Wallace (MBA ’07) of Good Start Genetics noted that the BPC is an effective way to meet...
View Details
- 01 Oct 2001
- News
Philip L. Yeo: The Next Big Thing
sciences and bioengineering. "In the next generation, we will know the genetic and molecular mechanisms of disease," Yeo declares. "Biomedical science will control and eradicate cancer and AIDS, and individualized medicine will be the...
View Details
Keywords:
Government
- 06 Sep 2016
- News
Connecting Past and Present
Family health was the impetus for Stanley Diamond (MBA 1958), founder of one of the world’s largest genealogy resources. “My family carries the beta thalassemia genetic trait,” a blood disorder. When my nephew was diagnosed, and we then...
View Details
- 24 Apr 2014
- News
Founding a bone marrow donor bank that saves thousands of lives
in the world, helping thousands of patients with leukemia and other life-threatening diseases in need of matching donors to save their lives. Because a close genetic match is necessary, even with a registry of millions, 6 out of 10...
View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
question—it’s clear.” Simply put, inefficiencies in the development of precision medicine can best be addressed by a business-analysis approach. With the mapping of the human genome completed 15 years ago, the sci-fi concept of using a cancer patient’s View Details
- 14 Jul 2009
- First Look
First Look: July 14
Course MaterialsThe DiagnoFirst Opportunity Harvard Business School Case 309-112 John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a View Details
Keywords:
Martha Lagace
- 03 Mar 2015
- First Look
First Look: March 3
a lower price but charge more for the cartridges necessary to run a sample and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost, but use the data customers generated to create a proprietary database of...
View Details
Keywords:
Sean Silverthorne
- February 2008 (Revised August 2008)
- Case
EXACT Sciences Corp.: Commercializing a Diagnostic Test
This case addresses the challenges of commercializing molecular diagnostics. Along the way, it explains the technology, payment system, and the measures used to assess the value of a diagnostic test.
View Details
Keywords:
Health Testing and Trials;
Genetics;
Science-Based Business;
Commercialization;
Biotechnology Industry
Herzlinger, Regina E. "EXACT Sciences Corp.: Commercializing a Diagnostic Test." Harvard Business School Case 308-090, February 2008. (Revised August 2008.)
- 16 Mar 2015
- News
A Sustainable Approach to Physics Education
Ogden, who grew up in a working-class family, recalls the power of his own education, leading up to his time at HBS, where the idea of paying it forward was part of the School’s DNA. “There’s something in the genetic code of the School...
View Details
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
cells in cancer patients) generated more than $2 billion in sales last year. Millennium Pharmaceuticals: Alan Crane (photo: Shelly R. Harrison) As the ability to analyze a patient's genetic material is developed, however, many believe...
View Details
- 15 Dec 2015
- News
The Year in Ideas 2015
qualities, achieved through the controversial technology of genetic modification. Genetically modified foods, also known as GMOs, are a confusing topic for consumers. In the United States, 95 percent of the...
View Details
- October 2001 (Revised March 2008)
- Case
Anagene, Inc.
By: Robert S. Kaplan and Christina L. Darwall
An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating...
View Details
Keywords:
Cost Accounting;
Financial Reporting;
Production;
Performance Capacity;
Risk and Uncertainty;
Genetics;
Governing and Advisory Boards;
Biotechnology Industry;
California
Kaplan, Robert S., and Christina L. Darwall. "Anagene, Inc." Harvard Business School Case 102-030, October 2001. (Revised March 2008.)
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would...
View Details
Keywords:
Genetics;
Business Growth and Maturation;
Business Plan;
Competition;
Venture Capital;
Biotechnology Industry
Hamermesh, Richard G., Mara Aspinall, and Phillip Andrews. "Gene Sequencing: Staking a Position in an Expanding Industry." Harvard Business School Case 812-004, October 2011.
- 01 Jun 2018
- News
Floor It
The sci-fi future for cancer treatment has become a reality, with breakthrough therapies that can use a cancer patient’s genetic information to create personalized treatments or employ the body’s immune response to treat disease. But for...
View Details
Keywords:
Julia Hanna; illustration by Mengxin Li
- 01 Mar 2017
- News
Alumni Take Cold Calls in New York City
focused on 23andMe, whose sale of genetic testing kits directly to consumers was challenged by the Food & Drug Administration. Quelch, who coauthored the case, is also on the faculty of the Harvard T.H. Chan School of Public Health. The...
View Details
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in...
View Details
Keywords:
Genetics;
Information Technology;
Business Model;
Disruptive Innovation;
Biotechnology Industry;
Information Technology Industry;
Semiconductor Industry;
Medical Devices and Supplies Industry
Yoffie, David B., Dharmesh M Mehta, and Rachel Sha. "Note on the Convergence Between Genomics & Information Technology." Harvard Business School Background Note 705-500, June 2005. (Revised July 2006.)
- 23 Nov 2010
- First Look
First Look: November 23
case:http://cb.hbsp.harvard.edu/cb/product/811014-PDF-ENG Generation Health: A Pioneer in Genetics Benefit Management (A) Robert F. Higgins, Jeffrey D. Marrazzo, and Rachel GordonHarvard Business School Case 810-007 Generation Health, a...
View Details
Keywords:
Sean Silverthorne